skip to Main Content

Cancer Services

Lung Cancer

Please see below all current lung cancer clinical trials of the Central Coast Cancer Centre.

Name: DREAM3R

A phase 3 Randomised trial DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma.

Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Lung Cancer- Mesothelioma
External page link More information about DREAM3R

Name: PACIFIC 9 

Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.

Principal Investigator: Dr Matthew Chan
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Non-Small Lung Cancer
External page link More information about PACIFIC 9

Name: LAGOON

A Randomised, Multicentre, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) In Relapsed Small Cell Lung Cancer (SCLC) patients. LAGOON.

Principal Investigator: Dr Matthew Wong
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Small Cell Lung Cancer
External page link More information about LAGOON

Name: HLX10-020-SCLC302

A randomised, double-blind, International Multicentre, Phase III Study to evaluate the Efficacy and safety of HLX10 in combination with Chemotherapy and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer.

Principal Investigator: Dr Matthew Chan
Study Coordinator: Cassandra Rubio
Status: Recruiting
Condition: Small Cell Lung Cancer
External page link More information about HLX10-020-SCLC302

More information

For more information about medical oncology clinical trials please contact the Nurse Unit Manager on 02 4320 9890 or see:

Internal page Research and Clinical Trials

Back To Top